Measuring the Balance Improvement on Multiple Sclerosis Patients After a Short Training Period With an APOS (All Phase Of Step Cycle) Kit

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00338637
Recruitment Status : Unknown
Verified June 2006 by Sheba Medical Center.
Recruitment status was:  Recruiting
First Posted : June 20, 2006
Last Update Posted : June 20, 2006
Information provided by:
Sheba Medical Center

Brief Summary:

Randomised double blind study of two parallel groups,one of the groups trained with the full APOS kit (a shoe with an additional bio mechanical device)

The control group trained with the Apos shoe without the bio mechanical device. both groups will be checked at the beginning of the study, one month later and at the end of the study after two months. The tests include neurological test, functional test(FSST,up and go test and berg balance test) gate analysis and quality fo life (rays) test.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Balance Cerebelar Impairment Device: APOS shoe kit Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : April 2006
Estimated Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. functional tests

Secondary Outcome Measures :
  1. gait analysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of Multiple sclerosis Cerebellar impairment EDSS under 4.5 age 18-65 years signed informed consent form

Exclusion Criteria:

  • pregnancy
  • coronary event in last 6 month
  • 30 days or less after acute attack
  • steroidal treatment in the last 60 days
  • alcohol abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00338637

Contact: Ofer Gal, Dr. 972-3-5303932

Sheba Medical Center Recruiting
Ramat Gan, Israel
Contact: Anat Achiron, Prof.    972-3-5303932   
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Anat Achiron, Prof. Sheba Medical Center Identifier: NCT00338637     History of Changes
Other Study ID Numbers: SHEBA-06-4127-AA-CTIL
First Posted: June 20, 2006    Key Record Dates
Last Update Posted: June 20, 2006
Last Verified: June 2006

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases